An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial-Reference-Cited by-同舟云学术

An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial

Published:2003-01 Issue:2-3 Volume:109 Page:101-108
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Massicotte Patricia,Julian Jim A,Gent Michael,Shields Karen,Marzinotto Velma,Szechtman Barbara,Chan Anthony K,Andrew Maureen

Publisher

Elsevier BV

Subject

Hematology

Reference21 articles.

1. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry;Monagle;Pediatr. Res.,2000

2. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications;Massicotte;J. Pediatr.,1998

3. Neonatal thrombosis: report of a prospective Canadian and international registry;Schmidt;Pediatrics,1995

4. Development of the human coagulation system in the full-term infant;Andrew;Blood,1987

5. Development of the human coagulation system in the healthy premature infant;Andrew;Blood,1988

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Thrombotic Complications in Pediatric Cancer;Children;2024-09-06

2. A Randomized, Controlled Trial of Continuous Heparin Infusion to Prevent Asymptomatic Catheter-Related Thrombosis at Discharge in Infants After Cardiac Surgery: The CHIP-CRT Trial;Journal of Pediatric Hematology/Oncology;2024-06-25

3. Efficacy and safety of antithrombotic therapy for preventing and treating pediatric thromboembolic disease: a systematic review;Scientific Reports;2024-06-11

4. Evaluation of the Safety and Efficacy of Enoxaparin Once-Daily Versus Twice-Daily Dosing for Prophylaxis in Pediatric Patients;The Journal of Pediatric Pharmacology and Therapeutics;2024-04-01

5. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial;The Lancet Haematology;2024-01